FDA rejected MDMA for PTSD therapy, demands more data. Concerns arise over U.S. readiness for legal psychedelics in healthcare.
Clinical trials show promising results for MDMA-assisted PTSD therapy. 71% no longer meet PTSD criteria after treatment, urging FDA to reconsider.
FDA's decision challenges psychedelics' place in U.S. healthcare. Industry faces workforce shortage, insurance, safety, and illegality concerns.
Collection
[
|
...
]